CSPG4 and central nervous system cancer: First we investigated the efficacy of the combination treatment in eradicating U87MG gliomas that are 99.2±0.2 % (n=3) NG2/CSPG4 positive, as recognized by mAb9.2.27 (Supplementary Fig. 1A).